CytoSorbents' Rights Offering Details
CytoSorbents Corporation (NASDAQ: CTSO) is pioneering advanced solutions in blood purification aimed at treating critical conditions within intensive care and cardiac surgery settings. The company is excited to announce its upcoming Rights Offering, aimed at enhancing its financial capabilities to further its innovative healthcare solutions.
Subscription Rights and Purchase Opportunities
Investors who hold shares of CTSO stock by the end of Nasdaq trading are encouraged to participate in this Rights Offering. Each stockholder of record will be granted a non-transferable Subscription Right Warrant for every share they hold, which can be exercised prior to the deadline of January 10. Exercising these rights allows stockholders to purchase Units priced at just $1.00 each. A typical Unit includes one share of common stock plus two transferable short-term Right Warrants.
Potential Financial Benefits
The funds raised through this offering are expected to significantly boost CytoSorbents' liquidity. By raising between $3.0 million and $5.0 million, the company will unlock an equivalent amount in restricted cash on its balance sheet, thus enhancing operational assets significantly. This influx of cash will set the stage for advancing CytoSorbents' product applications, especially as they await regulatory decisions concerning their DrugSorb-ATR marketing applications in the near future.
Understanding the Rights Offering Structure
Each Subscription Right warrants stockholders the right—though not the obligation—to purchase the Units at the affordable subscription price. Each Unit is substantially more than just a share; it consist of additional incentives to further enhance shareholder value:
- One common stock share.
- One Series A Right Warrant, allowing for the purchase of an extra share within a 45-day timeframe, priced favorably based on the volume-weighted average price.
- One Series B Right Warrant, with a 90-day exercise window after the closing date, ensuring timely opportunities for shareholders.
Dealing with Oversubscription Preferences
Additionally, shareholders holding their Subscription Rights can also exercise oversubscription privileges—in the case where they wish to buy more Units than initially available. If there are more demand and interest in Units than what is available, Units will be allocated on a pro-rata basis, ensuring fairness across all investors.
Anticipated Timeline for Subscription Rights
The company plans to send out Subscription Rights certificates and relevant prospectus materials to eligible stockholders shortly after the record date. Those who own shares in “street name” through brokerage accounts will be guided on how to proceed with the exercise of their rights digitally via their financial intermediaries.
About CytoSorbents Corporation
Driven by innovation in the field of blood purification, CytoSorbents is at the forefront of critical care solutions that address life-threatening conditions. Their flagship product, CytoSorb, is renowned globally and utilized extensively across numerous medical applications, especially in surgeries that require the removal of harmful substances from the bloodstream.
Aside from CytoSorb, the company is actively developing the DrugSorb-ATR, an advanced system aimed at minimizing perioperative bleeding risks among patients undergoing high-risk surgeries.
Frequently Asked Questions
What is the purpose of the Rights Offering by CytoSorbents?
The Rights Offering aims to secure funds for general corporate purposes and to enhance liquidity by unlocking restricted cash, thereby supporting ongoing operations and product launches.
How do stockholders participate in the Rights Offering?
Stockholders need to hold shares by the close of Nasdaq trading and will receive Subscription Right Warrants, which can be exercised to purchase additional Units at a predetermined price.
What does each Unit consist of in the Rights Offering?
Each Unit includes one share of common stock and two Right Warrants, providing opportunities for additional shares at favorable terms.
What are oversubscription privileges in this offering?
Oversubscription privileges allow shareholders the opportunity to purchase more Units than allocated if excess Units are available post the subscription process.
How can I get more information about the Rights Offering?
For further information, stockholders can reach out to D.F. King & Co., Inc., or refer to the company's investor relations section for detailed insights and updates.
